FLT3 and acute myeloid leukemia: For example, lestaurtinib following salvage chemotherapy elicited no improvement in response rates or OS compared with salvage chemotherapy alone in patients with relapsed FLT3-mutated AML [63], and combining lestaurtinib with intensive chemotherapy yielded no overall clinical benefit in patients with newly diagnosed FLT3-ITD-mutated AML [64].